Adalta

Adalta Equity

The The Equity of Adalta (1AD.AX) as of Oct 21, 2026 is 370,173.00 AUD. In the previous year, The Equity was -598,244.00 AUD — a change of -161.88% (higher).

Equity

370,173.00AUD

YoY

-161.88%

Last updated:

In 2026, Adalta's equity was 370,173.00 AUD, a -161.88% increase from the -598,244.00 AUD equity in the previous year.

The Adalta Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
7.49 M AUD
Jan 1, 2020
3.70 M AUD
Jan 1, 2021
6.39 M AUD
Jan 1, 2022
5.38 M AUD
Jan 1, 2023
1.91 M AUD
Jan 1, 2024
2.03 M AUD
Jan 1, 2025
-598,244.00 AUD
Jan 1, 2026
370,173.00 AUD
The Adalta Equity history
YEAREquityYoY
370,173.00AUD-161.88%
-598,244.00AUD-129.46%
2.03 MAUD+6.31%
1.91 MAUD-64.49%
5.38 MAUD-15.78%
6.39 MAUD+72.51%
3.70 MAUD-50.58%
7.49 MAUD+83.94%
4.07 MAUD-47.42%
7.75 MAUD-27.04%
10.62 MAUD+1,403.88%
705,890.00AUD+308.46%
172,816.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adalta Stock analysis

What does Adalta do? AdAlta Ltd. operates as a biotechnology company that discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies. Adalta is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Adalta's Equity

Adalta's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Adalta's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Adalta's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Adalta's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Adalta’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Adalta stock

The Equity of Adalta is 370,173.00 AUD in 2026.

The Equity of Adalta changed from -598,244.00 AUD to 370,173.00 AUD, representing a -161.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Adalta since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Adalta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Adalta

All Key Metrics — Adalta